CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.

Publication

Citation
Pruitt JR, Batt DG, Wacker DA, Bostrom LL, Booker SK, McLaughlin E, Houghton GC, Varnes JG, Christ DD, Covington M, Das AM, Davies P, Graden D, Kariv I, Orlovsky Y, Stowell NC, Vaddi KG, Wadman EA, Welch PK, Yeleswaram S, Solomon KA, Newton RC, Decicco CP, Carter PH, Ko SS.: CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett, Volume 17 (11), 2007
Authors
Batt DG, Booker SK, Bostrom LL, Carter PH, Christ DD, Covington M, Das AM, Davies P, Decicco CP, Graden D, Houghton GC, Kariv I, Ko SS., McLaughlin E, Newton RC, Orlovsky Y, Pruitt JR, Solomon KA, Stowell NC, Vaddi KG, Varnes JG, Wacker DA, Wadman EA, Welch PK, Yeleswaram S
Journal
Bioorg Med Chem Lett
Year
2007
PubMed
17418570
Machine-readable
REST APIRDF
Palacky University Olomouc

Palacky University Olomouc

Faculty of Science

Department of Physical Chemistry

tř. 17. listopadu 1192/12

771 46 Olomouc

Czech Republic

How to cite?

Juračka J., Šrejber M., Melíková M., Bazgier V., Berka K.: MolMeDB: Molecules on Membranes Database. Database, Volume 2019, 2019, baz078, https://doi.org/10.1093/database/baz078

Follow us

FacebookGithub

Financial Support

  • MolMeDB interoperability with UniProt and SwissLipids – MEYS Czech-Swiss project ELIXIR-IMPACT 8K0208 (2026–2028)
ELIXIRGAČRUP Olomouc
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. | MolMeDB